FULC vs. MELI

Last updated Apr 2, 2026

Compare and contrast key facts about Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI).

Performance

FULC vs. MELI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). The values are adjusted to include any dividend payments, if applicable.

FULC vs. MELI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
FULC Fulcrum Therapeutics, Inc.	-33.86%	140.64%	-30.37%	-7.28%	-58.85%	51.07%	-29.63%	23.26%
MELI MercadoLibre, Inc.	-14.66%	18.46%	8.20%	85.71%	-37.24%	-19.51%	192.90%	-11.83%

Fundamentals

Market Cap FULC : $473.90M MELI : $87.15B
EPS FULC : -$1.19 MELI : $39.39
PB Ratio FULC : 1.36 MELI : 12.91
Total Revenue (TTM) FULC : $0.00 MELI : $28.89B
Gross Profit (TTM) FULC : $0.00 MELI : $12.86B
EBITDA (TTM) FULC : -$84.77M MELI : $4.02B

Returns By Period

In the year-to-date period, FULC achieves a -33.86% return, which is significantly lower than MELI's -14.66% return.

FULC

• 1D: -2.48%
• 1M: -4.23%
• YTD: -33.86%
• 6M: -19.83%
• 1Y: 171.01%
• 3Y*: 37.94%
• 5Y*: -9.02%
• 10Y*: —

MELI

• 1D: -0.58%
• 1M: -3.27%
• YTD: -14.66%
• 6M: -21.04%
• 1Y: -10.24%
• 3Y*: 9.26%
• 5Y*: 2.62%
• 10Y*: 30.50%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

FULC vs. MELI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FULC

FULC Risk / Return Rank: 86
FULC Sharpe Ratio Rank: 88
FULC Sortino Ratio Rank: 90
FULC Omega Ratio Rank: 86
FULC Calmar Ratio Rank: 84
FULC Martin Ratio Rank: 83

MELI

MELI Risk / Return Rank: 28
MELI Sharpe Ratio Rank: 29
MELI Sortino Ratio Rank: 26
MELI Omega Ratio Rank: 26
MELI Calmar Ratio Rank: 31
MELI Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FULC vs. MELI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FULC	MELI	Difference
Sharpe ratio Return per unit of total volatility	1.83	-0.26	+2.09
Sortino ratio Return per unit of downside risk	2.89	-0.11	+3.01
Omega ratio Gain probability vs. loss probability	1.35	0.99	+0.36
Calmar ratio Return relative to maximum drawdown	2.91	-0.31	+3.21
Martin ratio Return relative to average drawdown	7.58	-0.68	+8.25
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

FULC vs. MELI - Sharpe Ratio Comparison

The current FULC Sharpe Ratio is 1.83, which is higher than the MELI Sharpe Ratio of -0.26. The chart below compares the historical Sharpe Ratios of FULC and MELI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	FULC	MELI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.83	-0.26	+2.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.08	0.05	-0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.63	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.08	0.46	-0.53

Correlation

The correlation between FULC and MELI is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

FULC vs. MELI - Dividend Comparison

Neither FULC nor MELI has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
FULC Fulcrum Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MELI MercadoLibre, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.19%	0.38%	0.36%

Drawdowns

FULC vs. MELI - Drawdown Comparison

The maximum FULC drawdown since its inception was -92.70%, roughly equal to the maximum MELI drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for FULC and MELI.

Drawdown Indicators

	FULC	MELI	Difference
Max Drawdown Largest peak-to-trough decline	-92.70%	-89.49%	-3.21%
Max Drawdown (1Y) Largest decline over 1 year	-54.93%	-38.80%	-16.13%
Max Drawdown (5Y) Largest decline over 5 years	-92.70%	-68.64%	-24.06%
Max Drawdown (10Y) Largest decline over 10 years	—	-69.12%	—
Current Drawdown Current decline from peak	-75.85%	-34.23%	-41.62%
Average Drawdown Average peak-to-trough decline	-62.28%	-23.48%	-38.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.08%	17.58%	+3.50%

Volatility

FULC vs. MELI - Volatility Comparison

Fulcrum Therapeutics, Inc. (FULC) has a higher volatility of 21.01% compared to MercadoLibre, Inc. (MELI) at 11.74%. This indicates that FULC's price experiences larger fluctuations and is considered to be riskier than MELI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	FULC	MELI	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.01%	11.74%	+9.27%
Volatility (6M) Calculated over the trailing 6-month period	68.96%	31.17%	+37.79%
Volatility (1Y) Calculated over the trailing 1-year period	94.30%	38.97%	+55.33%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	108.64%	49.47%	+59.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	111.22%	48.61%	+62.61%

Financials